<DOC>
	<DOCNO>NCT00779675</DOCNO>
	<brief_summary>This prospective Phase 4 , open-label , non-randomized , observational , multi-center study infliximab participant plaque-type psoriasis assess clinical response real-world practice long-term maintenance therapy infliximab 5 mg/kg body weight psoriasis population , prescribe regimen accordance product monograph ( PM ) Canada , approve summary sheet product characteristic ( SPC ) country European Union ( EU ) , per label accord local guideline participate country .</brief_summary>
	<brief_title>Assessment Long-Term Infliximab Psoriasis ( P05319 )</brief_title>
	<detailed_description>This study conduct two phase : 50-week treatment period 48-week extended treatment period .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Participant must diagnosis plaquetype psoriasis Participant 's physician must decide , subject 's consent , start treatment infliximab Participant must demonstrate willingness participate study agree procedure study sign write informed consent For inclusion extend treatment period , participant must complete 50 week infliximab treatment treatment period For inclusion extend treatment period , participant must continue treatment intravenous infliximab For inclusion extend treatment period , participant must improvement PASI score great equal 25 % time entry extend treatment period For Treatment Period Given noninterventional nature study , specific exclusion criterion apply participant long participant eligible trial ( Inclusion Criteria ) . The treat physician expect , normal clinical practice , follow PM ( Canada ) , approve SPC ( EU ) , local labeling ( participate country ) regard contraindication precaution For Extended Treatment Period Given noninterventional nature study , specific exclusion criterion apply participant long participant receive infliximab treatment accordance PM ( Canada ) , approve SPC ( EU ) , local labeling ( participate country ) regard contraindication , precaution , dose frequency administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>